The safety of polymyxin antibiotics

Bibliography

• Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin patients with renal disease. N Engl J Med 1962;266:759–62
   PubMed Web of Science ®Google Scholar
• Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857–68
   PubMedGoogle Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27
   PubMed Web of Science ®Google Scholar
• Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977;46:723–63
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333–41
   PubMed Web of Science ®Google Scholar
• Danner RL, Joiner KA, Rubin M, et al. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 1989;33:1428–34
   PubMed Web of Science ®Google Scholar
• Vaara M. Novel derivatives of polymyxins. J Antimicrob Chemother 2013;68:1213–19
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589–601
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284–94
   PubMed Web of Science ®Google Scholar
• Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115–21
   PubMed Web of Science ®Google Scholar
• Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78–83
   PubMed Web of Science ®Google Scholar
• Claus BO, Snauwaert S, Haerynck F, et al. Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients. Int J Clin Pharm 2015;37(4):555–8
   Google Scholar
• Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005;37:142–5
   PubMed Web of Science ®Google Scholar
• Teng CB, Koh PT, Lye DC, Ang BS. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents 2008;31:80–2
   PubMed Web of Science ®Google Scholar
• Vasen W, Desmery P, Ilutovich S, Di Martino A. Intrathecal use of colistin. J Clin Microbiol 2000;38:3523
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME. Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect 2005;50:348–52
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003;47:1364–70
   PubMed Web of Science ®Google Scholar
• Promixin 1 MIU powder for nebuliser solution [package insert]. West Sussex, UK: Profile Pharma Limited; 2003;2003
   Google Scholar
• Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008;30:143–51
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430–6
   PubMed Web of Science ®Google Scholar
• Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012;54:670–80
   PubMed Web of Science ®Google Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008;56:432–6
   PubMed Web of Science ®Google Scholar
• Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013;141:1214–22
   PubMed Web of Science ®Google Scholar
• Gu WJ, Wang F, Tang L, et al. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. Int J Antimicrob Agents 2014;44:477–85
   PubMed Web of Science ®Google Scholar
• Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010;65:1019–27
   PubMed Web of Science ®Google Scholar
• Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010;65:2231–7
   PubMed Web of Science ®Google Scholar
• Kwon KH, Oh JY, Yoon YS, et al. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes. Int J Antimicrob Agents 2015;45:605–9
   PubMed Web of Science ®Google Scholar
• Gauthier TP, Wolowich WR, Reddy A, et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012;56:2392–6
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Behle TF, Falci DR, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 2015;70:1552–7
   PubMed Web of Science ®Google Scholar
• Ko H, Jeon M, Choo E, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011;117:c284–8
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014;43:349–52
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35:194–9
   PubMed Web of Science ®Google Scholar
• Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012;54:1720–6
   PubMed Web of Science ®Google Scholar
• Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013;57:524–31
   PubMed Web of Science ®Google Scholar
• Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010;54:1117–24
   PubMed Web of Science ®Google Scholar
• Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:3624–30
   PubMed Web of Science ®Google Scholar
• Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48:1724–8
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005;5:1
   PubMed Web of Science ®Google Scholar
• Kubin CJ, Ellman TM, Phadke V, et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012;65:80–7
   PubMed Web of Science ®Google Scholar
• Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010;35:473–7
   PubMed Web of Science ®Google Scholar
• Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy 2013;33:812–16
   PubMed Web of Science ®Google Scholar
• Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011;31:1257–64
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011;53:879–84
   PubMed Web of Science ®Google Scholar
• Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503–5
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Prado GV, Costa SF, et al. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 2009;65:431–4
   PubMed Web of Science ®Google Scholar
• Nord NM, Hoeprich PD. Polymyxin B and Colistin. A critical comparison. N Engl J Med 1964;270:1030–5
   PubMed Web of Science ®Google Scholar
• Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013;57:1300–3
   PubMed Web of Science ®Google Scholar
• Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014;58:2740–6
   PubMed Web of Science ®Google Scholar
• Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659–62
   PubMed Web of Science ®Google Scholar
• Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566–9
   PubMed Web of Science ®Google Scholar
• Yousef JM, Chen G, Hill PA, et al. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011;55:4044–9
   PubMed Web of Science ®Google Scholar
• Yousef JM, Chen G, Hill PA, et al. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 2012;67:452–9
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yamaguchi H, Ogura J, et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 2013;57:6319–24
   PubMed Web of Science ®Google Scholar
• Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004;286:C913–22
   PubMed Web of Science ®Google Scholar
• Berg JR, Spilker CM, Lewis SA. Modulation of polymyxin B effects on mammalian urinary bladder. Am J Physiol 1998;275:F204–15
   PubMed Web of Science ®Google Scholar
• Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005;26:504–7
   PubMed Web of Science ®Google Scholar
• Mostardeiro MM, Pereira CA, Marra AR, et al. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother 2013;57:1442–6
   PubMed Web of Science ®Google Scholar
• Korbila IP, Michalopoulos A, Rafailidis PI, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010;16:1230–6
   PubMed Web of Science ®Google Scholar
• Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009;34:434–8
   PubMed Web of Science ®Google Scholar
• Sorli L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 2013;13:380
   PubMed Web of Science ®Google Scholar
• Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 2013;17:R174
   PubMed Web of Science ®Google Scholar
• Lee YJ, Wi YM, Kwon YJ, et al. Association between colistin dose and development of nephrotoxicity. Crit Care Med 2015;43:1187–93
   PubMed Web of Science ®Google Scholar
• Omrani AS, Alfahad WA, Shoukri MM, et al. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob 2015;14:3
   PubMed Web of Science ®Google Scholar
• Ceylan B, Tanis M, Akkoyunlu ME, et al. Variables determining the development of colistin-associated renal impairment. Wien Klin Wochenschr 2015. [Epub ahead of print]
   Google Scholar
• Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010;51:1238–44
   PubMed Web of Science ®Google Scholar
• Fekety FRJr, Norman PS, Cluff LE. The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 1962;57:214–29
   PubMed Web of Science ®Google Scholar
• Lamb R. Colistin sulphate in the treatment of specific bacterial intestinal infections. Scott Med J 1968;13:9–12
   PubMedGoogle Scholar
• Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008–11
   PubMed Web of Science ®Google Scholar
• Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62:39–47
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:3136–46
   PubMed Web of Science ®Google Scholar
• Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31:1058–65
   PubMed Web of Science ®Google Scholar
• Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007;33:1162–7
   PubMed Web of Science ®Google Scholar
• Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11:402–6
   PubMed Web of Science ®Google Scholar
• Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185–90
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 2009;33:503e501–13
   Web of Science ®Google Scholar
• Montero M, Horcajada JP, Sorli L, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009;37:461–5
   PubMed Web of Science ®Google Scholar
• Cheng CY, Sheng WH, Wang JT, et al. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297–300
   PubMed Web of Science ®Google Scholar
• Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011;62:187–90
   PubMed Web of Science ®Google Scholar
• Turkoglu M, Dizbay M, Ciftci A, et al. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Int J Antimicrob Agents 2012;39:142–5
   PubMed Web of Science ®Google Scholar
• Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries 2015;9:476–85
   PubMed Web of Science ®Google Scholar
• Polat M, Kara SS, Tapisiz A, et al. Treatment of ventilator-associated pneumonia using intravenous colistin alone or in combination with inhaled colistin in critically ill children. Paediatr Drugs 2015;17(4):323–30
   PubMed Web of Science ®Google Scholar
• Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010;65:2645–9
   PubMed Web of Science ®Google Scholar
• Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013;56:398–404
   PubMed Web of Science ®Google Scholar
• Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46:678–85
   PubMed Web of Science ®Google Scholar
• Temocin F, Erdinc S, Tulek N, et al. Colistin-Associated Nephrotoxicity and Risk Factors. Jpn J Infect Dis 2015;68(4):318–20
   PubMed Web of Science ®Google Scholar
• Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med 2015;43:1194–204
   PubMed Web of Science ®Google Scholar
• Holloway KP, Rouphael NG, Wells JB, et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006;40:1939–45
   PubMed Web of Science ®Google Scholar
• Mendes CA, Cordeiro JA, Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother 2009;43:1948–55
   PubMed Web of Science ®Google Scholar
• Esaian D, Dubrovskaya Y, Phillips M, Papadopoulos J. Effectiveness and tolerability of a polymyxin B dosing protocol. Ann Pharmacother 2012;46:455–6
   PubMed Web of Science ®Google Scholar
• Dubrovskaya Y, Prasad N, Lee Y, et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother 2015;70:1903–7
   PubMed Web of Science ®Google Scholar
• Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med 1973;56:31–5
   PubMedGoogle Scholar
• Shrestha A, Soriano SM, Song M, Chihara S. Intravenous colistin-induced acute respiratory failure: A case report and a review of literature. Int J Crit Illn Inj Sci 2014;4:266–70
   Google Scholar
• Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005;127:522–9
   PubMed Web of Science ®Google Scholar
• Hoeprich PD. The polymyxins. Med Clin North Am 1970;54:1257–65
   PubMed Web of Science ®Google Scholar
• Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003;52:987–92
   PubMed Web of Science ®Google Scholar
• Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, et al. Preliminary clinical study of the effect of ascorbic Acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 2015;59:3224–32
   PubMed Web of Science ®Google Scholar
• Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 2015;35:28–33
   PubMed Web of Science ®Google Scholar
• Bode-Boger SM, Schopp B, Troger U, et al. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. Int J Antimicrob Agents 2013;42:357–60
   PubMed Web of Science ®Google Scholar
• Brandenburg KS, Rubinstein I, Sadikot RT, Onyuksel H. Polymyxin B self-associated with phospholipid nanomicelles. Pharm Dev Technol 2012;17:654–60
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006;12:1227–30
   PubMed Web of Science ®Google Scholar